Breast Cancer

Latest News

Data suggest trastuzumab deruxtecan and pertuzumab may represent a new first-line standard of care for metastatic, HER2-positive breast cancer. | Image credit: Axel Kock - stock.adobe.com

Trastuzumab Deruxtecan Plus Pertuzumab Improves PFS vs Standard Care in HER2+ Breast Cancer

By Rose McNulty

June 2nd 2025

Trastuzumab deruxtecan plus pertuzumab demonstrated statistically and clinically significant improvement in progression-free survival (PFS) in HER2-positive breast cancer, potentially representing a new standard of care.

AJMC

Comparing Breast Cancer Treatment Outcomes Between Fee-for-Service and Medicare Advantage

By Galen Shearn-Nance, BS
Rishi R. Sachdev, BS

April 4th 2025

Screen-detected breast cancer. | Image Credit: keetazalay - stock.adobe.com

Interval Breast Cancer Risk High Despite Screening, Highlights Need for Risk-Based Approach

By Cameron Santoro

March 27th 2025

Diverse women and breast cancer support | Image Credit: ©Atstock Productions-stock.adobe.com

Same-Day Breast Imaging Gaps Reveal Health Care Disparities

By Maggie L. Shaw

February 18th 2025

Pink ribbon for breast cancer | Image Credit: Andrey Popov - stock.adobe.com

Black Patients With Metastatic Triple-Negative Breast Cancer Are Less Likely to Get Immunotherapy, Study Finds

By Pearl Steinzor

February 17th 2025

Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

Experts discuss the impact of CDK4/G inhibitor use, including medication cost, total care costs, toxicity profiles, and strategies to manage and optimize patient outcomes in high-risk early breast cancer.

Watch the latest AJMC Peer Exchange on Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates

More News

December 14th 2019

Personalizing Breast Cancer: How Liquid Biopsy Testing for ctDNA, CTCs Can Promote Preventive Care

Matthew Gavidia

Two abstracts on liquid biopsy tests revealed the potential of analyzing circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in promoting heightened decision-making by clinicians for patients with early-stage and metastatic breast cancer.

December 14th 2019

Oral Paclitaxel Reveals Superior Confirmed Response, Survival in Patients With Metastatic Breast Cancer, Compared With IV Paclitaxel

Matthew Gavidia

In phase 3 trial results presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, oral paclitaxel with encequidar, the first orally administered paclitaxel, was shown to exhibit superior confirmed response and survival with less neuropathy for patients with metastatic breast cancer compared with intravenous (IV) paclitaxel.

Dr Rita Nanda Discusses What Findings of I-SPY2 Mean for Future Breast Cancer Treatments

December 13th 2019

Dr Rita Nanda Discusses What Findings of I-SPY2 Mean for Future Breast Cancer Treatments

Rita Nanda, MD, associate professor, medicine, The University of Chicago Medicine, outlines the design of the I-SPY2 clinical trial and what the results have been so far.

Dr Corey Speers on Challenges Adopting Personalized Radiation Therapy

December 13th 2019

Dr Corey Speers on Challenges Adopting Personalized Radiation Therapy

Ensuring that prognostic or predictive tests to help make decisions regarding radiation therapy are accurate and clinically validated remains a challenge, said Corey Speers, MD, PhD, assistant professor, radiation oncology, University of Michigan.

December 13th 2019

Age Associated With Benefit Derived From Chemotherapy for Women With Luminal Breast Cancer, MINDACT Trial Finds

Matthew Gavidia

Data from the MINDACT trial revealed that among women with luminal breast cancers (hormone receptor–positive, HER2-negative by local pathology) with a high clinical risk and low genomic risk, those aged 40 to 50 years had a greater, but insignificant, benefit from chemotherapy than patients older than 50.

Dr Nadine Tung Discusses When to Refer Patients for Germline Testing

December 13th 2019

Dr Nadine Tung Discusses When to Refer Patients for Germline Testing

The bar for who should get genetic testing for breast cancer keeps getting lowered, and oncologists have to keep informed about which results should trigger a referral for germline testing, said Nadine Tung, MD, director, Cancer Risk and Prevention Program, Beth Israel Deaconess Medical Center, and associate professor, medicine, Harvard Medical School.

Dr Eileen Rakovitch Outlines Use of Biomarkers to Treat Breast Cancer

December 13th 2019

Dr Eileen Rakovitch Outlines Use of Biomarkers to Treat Breast Cancer

Using biomarker tests can help personalize care for women with ductal carcinoma in situ and determine the risks of using or not using radiation, said Eileen Rakovitch, MD, MSc, FRCPC, professor, department of radiation oncology, University of Toronto.

December 12th 2019

Measuring Therapeutic Intervention Impact, Receptiveness for Patients With Breast Cancer

Matthew Gavidia

In 3 abstracts presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas, patient-reported outcomes (PROs) and quality of life were measured for different therapeutic interventions aiming to either heighten tumor detection or ease chemotherapy-induced effects.

December 12th 2019

Trastuzumab Deruxtecan Demonstrates Durable Efficacy in Phase 2 DESTINY-Breast01 Trial

Matthew Gavidia

Results from the phase 2 DESTINY-Breast01 clinical trial show the novel efficacy of trastuzumab deruxtecan in providing durable benefit to heavily pretreated patients having undergone other HER2-targeted treatments.

December 12th 2019

Follow-Up Data From Second OS Analysis of APHINITY Reveal Growing Impact of Pertuzumab Within Patient Subgroups

Matthew Gavidia

Overall survival was shown to be greater but insignificant in patients administered pertuzumab compared with placebo, while subgroups of lymph node–positive and hormone receptor–negative patients were distinguished as major beneficiaries, according to the results of the second interim analysis of APHINITY presented at the San Antonio Breast Cancer Symposium in San Antonio, Texas.

Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA

November 7th 2017

Incidence Rates of Early-Stage Breast and Colorectal Cancer Increased Following Enactment of ACA

Jaime Rosenberg

With the ACA putting emphasis on preventive care, there has been an immediate increase in breast and coloreactal cancer screenings. A recent study found that incidence rates of early-stage breast and colorectal cancer increased in 2014, but did not vary for late-stage breast and colorectal cancer.

September 5th 2017

Mammography Device Approved by FDA Gives Patients Control Over Pressure Levels

Christina Mattina

The FDA has approved the first 2D digital mammography system that lets patients adjust the level of compression applied to their breast during the imaging procedure.

November 10th 2016

Medical Home Transformation and Breast Cancer Screening

Amy W. Baughman, MD, MPH Phyllis Brawarsky, MPH Tracy Onega, PhD, MS Tor D. Tosteson, ScD Qianfei Wang, MS Anna N.A. Tosteson, ScD Jennifer S. Haas, MD, MSc

Breast cancer screening may not improve in early medical home implementation.

October 14th 2016

Breast Cancer Death Rates Drop, but Racial Disparities Linger

Christina Mattina

Data released by the CDC today indicate that while breast cancer deaths are on the decline, black women still have worse outcomes than white women. The report also noted disparate trends in breast cancer incidence among different races and age groups.

October 13th 2016

What We're Reading: Awaiting Alzheimer's Drug Clinical Trial Results

What we’re reading, October 13, 2016: researchers, Alzheimer’s patients, and their families anxiously await the results of a clinical trial that could help slow the disease’s progress; many breast cancers detected by mammograms are overtreated even though they likely would not be fatal on their own; stock prices fall for Humana and Cigna as CMS says a minority of their patients are in plans rated 4 stars or higher.

November 30th 2015

Does Telephone Scheduling Assistance Increase Mammography Screening Adherence?

Colleen A. Payton, MPH Mona Sarfaty, MD Shirley Beckett, AAS Carmen Campos, MPH Kathleen Hilbert, RN

The authors describe a quality improvement intervention that focuses on directly scheduling mammogram appointments for women who lack adherence despite written outreach letters.

November 13th 2015

Testing Novel Patient Financial Incentives to Increase Breast Cancer Screening

Elizabeth Levy Merrick, PhD, MSW Dominic Hodgkin, PhD Constance M. Horgan, ScD Laura S. Lorenz, PhD Lee Panas, MS Grant A. Ritter, PhD Paul Kasuba, MD Debra Poskanzer, MD Renee Altman Nefussy, BA

This study tested 3 financial incentives encouraging breast cancer screening (mammograms) among women deemed overdue. None were effective overall; "person-centered" incentives worked in the most recently screened subgroup.

March 21st 2014

Narrow Networks a Challenge for Patients with Cancer

Katie Sullivan, MA

Despite ACA stipulations, patients with cancer may face new barriers to care as they shop for healthcare plans on the state and federal insurance exchanges.

March 18th 2014

Colon Cancer Rates Drop in Older Americans, but Disparities Remain

Dramatic progress has been made in reducing colon cancer incidence and death rates in the U.S., but concerns remain about striking racial and socio-economic disparities, according to new national statistics on colorectal cancer.

March 3rd 2014

Integrating Genetic Counseling Into an Oncology Practice Can Benefit High-Risk Families

Genetic counseling-including testing and risk assessment-is one of the most rapidly growing areas of oncology and has become the standard of care for patients with a personal and family history of breast, ovary, or colon cancer.

Karen Lewis, MS, MM, CGC, Discusses Oncology and Genetic Testing

January 28th 2014

Karen Lewis, MS, MM, CGC, Discusses Oncology and Genetic Testing

Karen Lewis, MS, MM, CGC, says the goals of Healthy People 2020 are developed by looking at a variety of key areas in healthcare, and then choosing the most actionable items to improve the overall health of the general population.

January 17th 2014

Custom-Fit Treatments for Prostate Cancer

In a bid to improve treatment for men with high-risk prostate cancer, some researchers want to take a page from the playbook for breast cancer.

May 24th 2012

BRCA1/2 Genetic Testing Found Cost-Effective in Current Era

SABCS Conference Coverage

...

8 9 10 11 12 13 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences^® and AJMC®.
All rights reserved.

Editorial Boards

Do Not Sell My Information

Terms & Conditions